Twist Bioscience reported record Q3 2025 revenues of $96.1 million, marking an 18% year-over-year increase driven by 27% growth in next-generation sequencing and 7% growth in synthetic biology revenues. The company slightly narrowed its full-year revenue guidance to $374 million-$376 million. Growth was supported primarily by diagnostic testing and expanded academic market penetration. Despite strong top-line performance, shares declined amid cautious investor sentiment about future guidance and market conditions.